



HFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d)		Attny. Docket No. 2002B141/2
In Re Application of: Datta et al.		
U.S. Serial No. 10/688,091	Filing Date October 17, 2003	Examiner Unassigned
		Group Art Unit 1712

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR § 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:

the fee as set forth in § 1.17(p), or
 the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

37 CFR § 1.97(d)

The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

Legible copies of the references are enclosed.

This application is a:
 Continuation / Divisional,
 Continuation-in-Part,

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

July 06, 2004
Date

Date

Mandi B. McElrath

Mandi Milbank

Registration No. 50,853

ExxonMobil Chemical Company


Law Technology

P.O. Box 2149

NO. D-01-2149

(281) 834-1928 Voice

(281) 834-2495 Facsimile

INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> 				ATTY. DOCKET NO.	SERIAL NO.			
				2002B141/2	10/688,091			
				APPLICANT				
				Datta et al.				
				FILING DATE	GROUP			
				October 17, 2003	1712			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,959,030	09/28/99	Berta	525	64		
	AB	6,245,856	06/12/01	Kaufman et al.	525	240		
	AC	6,232,402	05/15/01	Demeuse	525	191		
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL	WO 97/20888	12/06/97	PCT	C08L	53/00		
	AM	EP 0 792 914	03/096/97	EUROPE	C08L	23/10		
	AN							
	AO							
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)								
	AP							
	AQ							
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant								